Tianjin Ringpu Bio-TechnologyLtd Past Earnings Performance
Past criteria checks 2/6
Tianjin Ringpu Bio-TechnologyLtd has been growing earnings at an average annual rate of 11%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 7.9% per year. Tianjin Ringpu Bio-TechnologyLtd's return on equity is 9.7%, and it has net margins of 17.6%.
Key information
11.0%
Earnings growth rate
6.9%
EPS growth rate
Pharmaceuticals Industry Growth
10.9%
Revenue growth rate
7.9%
Return on equity
9.7%
Net Margin
17.6%
Last Earnings Update
30 Sep 2024
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Tianjin Ringpu Bio-TechnologyLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
XSEC:300119 Revenue, expenses and earnings (CNY Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
30 Sep 24
2,409
424
582
183
30 Jun 24
2,354
434
564
179
31 Mar 24
2,339
460
563
177
31 Dec 23
2,249
453
555
172
30 Sep 23
2,195
387
548
182
30 Jun 23
2,170
385
531
160
31 Mar 23
2,136
355
518
143
01 Jan 23
2,084
347
507
132
30 Sep 22
1,985
354
555
105
30 Jun 22
1,875
349
530
113
31 Mar 22
1,838
369
511
114
01 Jan 22
2,007
413
547
117
30 Sep 21
2,038
438
522
124
30 Jun 21
2,117
454
548
120
31 Mar 21
2,106
441
552
116
31 Dec 20
2,000
398
551
111
30 Sep 20
1,895
302
549
102
30 Jun 20
1,737
255
527
97
31 Mar 20
1,613
224
495
94
31 Dec 19
1,467
194
440
94
30 Sep 19
1,346
158
399
89
30 Jun 19
1,260
137
373
84
31 Mar 19
1,203
124
373
79
31 Dec 18
1,190
119
360
80
30 Sep 18
1,179
108
371
81
30 Jun 18
1,157
117
301
123
31 Mar 18
1,112
112
321
105
31 Dec 17
1,047
105
343
85
30 Sep 17
1,008
136
341
61
30 Jun 17
993
138
402
0
31 Mar 17
988
140
398
0
31 Dec 16
970
133
391
0
30 Sep 16
943
129
357
0
30 Jun 16
905
113
364
0
31 Mar 16
832
108
337
0
31 Dec 15
793
110
334
0
30 Sep 15
690
68
330
0
30 Jun 15
639
43
340
0
31 Mar 15
625
34
346
0
31 Dec 14
585
27
327
0
30 Sep 14
669
95
323
0
30 Jun 14
676
113
304
0
31 Mar 14
722
140
299
0
31 Dec 13
755
152
302
0
Quality Earnings: 300119 has a large one-off gain of CN¥213.6M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 300119's current net profit margins (17.6%) are lower than last year (17.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300119's earnings have grown by 11% per year over the past 5 years.
Accelerating Growth: 300119's earnings growth over the past year (9.4%) is below its 5-year average (11% per year).
Earnings vs Industry: 300119 earnings growth over the past year (9.4%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 300119's Return on Equity (9.7%) is considered low.